Avacta Group PLC · LSE:AVCT
Avacta — Shareholder Meeting (June 2023)
46 slides from Avacta's shareholder meeting presentation, Jun 28, 2023
Slide 1: Avacta Group plc Business Review
Avacta Group plc Business Review Annual General Meeting of Shareholders 28th June 2023 The Royal Society of Medicine, 1 Wimpole Street, London
Slide 2: Disclaimer
Disclaimer No representation or warranty, expressed or implied, is made or given by or on behalf of Avacta Group plc (the “Company” and, together with its subsidiaries and subsidiary undertakings, the “Group”) or any of its directors or any other person as to the accuracy, completeness or fairness o
Slide 3: Avacta Group plc Review of the Year
Avacta Group plc Review of the Year Therapeutics Division Strategic Objectives 2022-23 • pre|CISIONTM platform proof-of-concept in human : “Chemotherapy targeted to the tumour” • Build value in the pre|CISIONTM pipeline • Progress the Affimer® platform towards the clinic Diagnostics Division Strateg
Slide 4: Delivering strategic objectives across the Group
Avacta Group plc Review of the Year Delivering strategic objectives across the Group June 23 AVA6000 escalation to 6th dose cohort • pre|CISIONTM platform PoC in human June 23 Appointment of Shaun Chilton as Non- • Build value in the pre|CISIONTM pipeline executive Director June 23 Achievement of Af
Slide 5: Avacta Group plc Board
Avacta Group plc Board Extensive commercial and drug development experience Dr Christina Coughlin Dr Mark Goldberg Dr Eliot Forster Non-executive Director Non-executive Director Chairman • Christina Coughlin, MD, PhD is former Chief Executive • Mark A. Goldberg, MD, is a medical oncologist and • For
Slide 6: Avacta Group plc Board
Avacta Group plc Board Extensive commercial and drug development experience Shaun Chilton Dr Trevor Nicholls Paul Fry Non-executive Director Non-executive Director, Chair of Remuneration Non-executive Director, Chair of Audit Committee Committee • Most recently Chief Executive Officer of the formerl
Slide 7: Avacta Therapeutics: Vision and Strategy
Avacta Therapeutics Improving cancer patients’ lives through innovation and partnership VISION STRATEGY Our vision is to deliver • Use our proprietary innovative oncology pre|CISIONTM and Affimer® drugs that transform platforms to develop best-in- treatment outcomes to class and first-in-class cance
Slide 8: AVA6000: A Tumour Targeted Form of Doxorubicin
AVA6000: A Tumour Targeted Form of Doxorubicin The Doxorubicin market is US$ 1,390.64 million in 2022 and expected to grow at a CAGR of 6.1% to reach US$ 1,983.40 million by 20281 • Doxorubicin has been a standard Soft Tissue Sarcoma Global Liposomal Doxorubicin Market of care first-line treatment f
Slide 9: ALS-6000-101 Phase I Dose Escalation Study
ALS-6000-101 Phase I Dose Escalation Study Positive safety profile and biopsies confirm the ability of pre|CISIONTM to target the release of doxorubicin in the tumour tissue at therapeutic levels • 29 patients with a range of solid tumours now dosed across five dose groups (80mg/m2 – 250mg/m2). • UK
Slide 10: AVA6000: Planned Phase Ib Study
AVA6000: Planned Phase Ib Study Development Rationale for AVA6000 in Soft Tissue Sarcoma (STS) • Advanced/metastatic soft tissue sarcoma (STS) tumours are highly FAP positive. • Doxorubicin is the standard of care for advanced STS. • Conventional doxorubicin has marginal efficacy & limitations due t
Slide 11: pre|CISION Commercial Strategy
pre|CISIONTM Commercial Strategy Entering commercial phase for pre|CISIONTM platform following excellent human safety data and proof-of-concept for tumour targeting via FAP AVA6000 • Progress AVA6000 through phase 1b to generate efficacy data and reach commercial stage for this asset • Efficacy data
Slide 12: AffyXell – Joint Venture in the Cell & Gene Therapy
AffyXell – Joint Venture in the Cell & Gene Therapy A joint venture in South Korea with Daewoong Pharmaceutical to develop engineered mesenchymal stem cells that express and secrete immuno-modulatory Affimer molecules to treat autoimmune diseases Next-generation Stem Cell Therapies • Renewable “off
Slide 13: LG Chem – Multi-target Partnership
LG Chem – Multi-target Partnership A multi-target development partnership and licensing deal worth up to $310 million with a focus on oncology and inflammatory diseases PDL1/XT Antagonist • PD1/PDL1 axis Affimer® inhibitor • Half-life extension using Affimer XT® a human serum albumin binder • Small
Slide 14: Avacta Diagnostics: M&A Led Growth Strategy
Avacta Diagnostics: M&A Led Growth Strategy VISION MISSION Build a full spectrum, Innovate to make market differentiated European in- leading diagnostic vitro diagnostics (IVD) business solutions available to all, supporting healthcare to inform treatment and professionals and broadening monitor hea
Slide 15: Avacta Diagnostics Review and Growth
Avacta Diagnostics REVIEW GROWTH • Diagnostics Division with • Organic growth through strong sales channels in UK expansion of Launch and France and a broad Diagnostics into Germany, portfolio of products for improved distribution of Coris professional healthcare and products and cross-group rapid,
Slide 16: Strategic Objectives 2023-24
Strategic Objectives 2023-24 A strategy to deliver long term sustainable value Therapeutics Division • Initiate and progress phase 1b • Commercialise the pre|CISIONTM platform • IND filing for the Affimer® platform • Progress AVA3996 through to IND filing Diagnostics Division • Establish Launch GmbH
Slide 17: Summary
Summary Principle of tumour targeting through FAP activation of pre|CISIONTM modified chemotherapy confirmed in AVA6000 phase 1 study. AVA3996, an FAP-activated proteasome inhibitor, showing positive pre-clinical data; now in IND enabling studies with FIH planned late 2024. First two acquisitions in
Slide 18: www.avacta.com
www.avacta.com
Slide 19: AVA6000 Phase 1a Clinical Study Update
AVA6000 Phase 1a Clinical Study Update – ALS-6000-101 Dr Andrew Saunders, Medical Advisor Annual General Meeting of Shareholders 28th June 2023 The Royal Society of Medicine, 1 Wimpole Street, London
Slide 20: AVA6000: A FAP-Targeted Next Generation Doxorubicin
AVA6000: A FAP-Targeted Next Generation Doxorubicin • Exploiting FAP specificity within the Doxorubicin is a very successful chemotherapy tumour by selectively cleaving AVA6000 & due to its efficacy in fighting a wide range of activating doxorubicin at tumour sites cancers….but it has limitations to
Slide 21: Phase 1 & 2 Study Designs
Phase 1 & 2 Study Designs AVA6000 in Patients with Advanced, Metastatic Solid Tumours Phase 1a: Dose Escalation Phase 1b: Dose Expansion Phase 2 310 mg/m2 Phase 1a (209mg/m2) Key Eligibility Criteria 250 mg/m2 • Locally Advanced, (169mg/m2) Metastatic Selected 200 mg/m2 RP2D Solid Tumours AVA6000 (1
Slide 22: Overview of Clinical Study ALS-600-101
Overview of Clinical Study ALS-600-101 Phase 1 Dose Escalation of AVA6000 across a range of solid tumours known to be FAP +ve Interim Data Supports AVA6000 Mechanism AVA6000 Dose Regimen - 3 weekly cycles (Doxorubicin Equivalent Dose) 29 patients dosed across 5 AVA6000 cohorts 310 mg/m2 • Median (ra
Slide 23: Patient Demographics & Baseline Characteristics
Patient Demographics & Baseline Characteristics Study ALS -6000-101 80mg/m2 120mg/m2 160mg/m2 200mg/m2 (n=4) (n=6) (n=6) (n=3) Median Age (range), years 58 (56-71) 58 (30-76) 63 (50-73) 63 (53-72) Female, n (%) 3 (75) 2 (33) 0 (0) 1 (33) Male, n (%) 1 (25) 4 (66) 6 (100) 2 (66) Race, n (%) White 3 (
Slide 24: AVA6000 Safety Profile (80-200 mg/m2 Q3W)
AVA6000 Safety Profile (80-200 mg/m2 Q3W) Treatment-Related Adverse Events Cohort 1 Cohort 2 Cohort 3 Cohort 4 Total 80mg/m2 120mg/m2 160mg/m2 200mg/m2 • Overall AVA6000 has a modest and predictable (N = 4) (N = 6) (N = 6) (N =3) (N=19) safety profile Dose Limiting Toxicity 0 1 0 0 1 (5%) • 2 patien
Slide 25: Safety Profile: AVA6000 vs Doxorubicin
Safety Profile: AVA6000 vs Doxorubicin 1 AVA6000 (80-200mg/m2 Q3W) 2 Doxorubicin (75mg/m2 Q3W) N = 19 N = 249 • No Dose related increase in frequency or severity Treatment-Emergent Median No. Cycles = 2 (Range 1-8) Median No. Cycles = 7 (Range 1-8) of AVA6000 TEAEs with increasing dose (80, 120, 160
Slide 26: Tumour Biopsy Data
Tumour Biopsy Data Plasma vs Biopsy Doxorubicin Concentrations DOX DOX AVA6000 Plasma Biopsy @24h DOX Ratio** Biopsy Cohort (Dox Dose) Patient @24h Biopsy:Plasma Source mg/m2 ng/g nM ng/ml 101-006 (1st) 4.9 135 248nM 28:1 Liver Cohort 1 80 (54) 101-006 4.9 43 79nM 9:1 Liver (2nd) 103-021* 4.4 376 69
Slide 27: AVA6000: Phase Ib Study
AVA6000: Phase Ib Study Clinical Development in Soft-Tissue Sarcoma (Phase 1 to 2) Development Rationale in Soft Tissue Sarcoma (STS) • Advanced, Metastatic STS tumours • Doxorubicin is the only therapy indicated for first-line monotherapy in advanced STS • No current or near future competition for
Slide 28: Soft Tissue Sarcoma Drugs in Development
Soft Tissue Sarcoma Drugs in Development • Modest number of products in clinical development for STS with majority of R&D activity in early stage • KOLs indicate no serious competition in Soft Tissue Sarcoma indication for 1st Line Therapy 28
Slide 29: Market Potential for AVA6000
Market Potential for AVA6000 • There is huge potential for an improved next generation doxorubicin product considering: • The market value being generated by current doxorubicin therapies and the expectation that doxorubicin- based therapies will continue to be a key approach for oncology treatment
Slide 30: AVA6000 Conclusions
AVA6000 Conclusions • Dose Escalation • AVA6000 has a modest and predictable safety profile across the dose range (80-200mg/m2) • PK data for released doxorubicin highlights a positive profile • Doxorubicin Exposure (AUC) & Maximal Concentrations (Cmax) substantially reduced across doses • Doxorubic
Slide 31: Investigators
Investigators United Kingdom United States Professor Chris Twelves, Chief Investigator Dr William D. Tap Leeds Teaching Hospitals NHS Trust, Leeds Memorial Sloan Kettering Cancer Centre, New York Professor Udai Banerji Dr Lee D. Cranmer Fred Hutchinson Cancer Centre, Seattle The Royal Marsden NHS Fo
Slide 32: Avacta Diagnostics
Avacta Diagnostics M&A-led Growth Strategy in the European Diagnostics Sector Annual General Meeting of Shareholders 28th June 2023 The Royal Society of Medicine, 1 Wimpole Street, London
Slide 33: Avacta Diagnostics: M&A Led Growth Strategy
Avacta Diagnostics: M&A Led Growth Strategy VISION MISSION Build a full spectrum, Innovate to make market differentiated European in- leading diagnostic vitro diagnostics (IVD) business solutions available to all, supporting healthcare to inform treatment and professionals and broadening monitor hea
Slide 34: A Full Spectrum IVD Business
A Full Spectrum IVD Business Supporting healthcare professionals ………. and broadening access to diagnostics Centralised Testing Decentralised Testing Pathology Laboratory Rapid PoC Tests Self-sampling Diagnostics Value Chain Research Product Manufacturing Sales and Logistics and Development Marketing
Slide 35: Rationale for Acquisition of Launch Diagnostics
Rationale for Acquisition of Launch Diagnostics Supporting Healthcare Professionals Improving Access Centralised Testing Decentralised Testing Pathology Laboratory Rapid PoC Tests Self-sampling Acquisition of a profitable Sales and Logistics and distribution channel into Marketing Distribution centr
Slide 36: Launch Diagnostics
Launch Diagnostics Key Facts Launch by Numbers • Founded in 1990 and headquartered in UK. • FY21 £14.17M core, non-COVID related business. • Launch provides immunodiagnostic and • Total FY21 revenue £32.75M. molecular test products, technical support and • £23.85M UK and £8.90M France/Benelux. maint
Slide 37: Launch Diagnostics: Growth Opportunities
Launch Diagnostics: Growth Opportunities Opportunities for growth in sales and margin through geographical expansion, cross-selling to customers gained during the pandemic and expansion of product range Investment in Sales and Portfolio Expansion Geographical Expansion Marketing • Investment in sale
Slide 38: Spotlight on HOB Autoimmune and Allergy Testing
Spotlight on HOB Autoimmune and Allergy Testing The HOB BioCLIAs are used to detect autoimmune disease and allergy in patients’ blood samples Target Market Hospitals with routine immunology laboratories. From small hospitals (utilizing the BioCLIA500) to large teaching hospitals (utilising the BioCL
Slide 39: Rationale for Acquisition of Coris BioConcept
Rationale for Acquisition of Coris BioConcept Supporting Healthcare Professionals Improving Access Centralised Testing Decentralised Testing Pathology Laboratory Rapid PoC Tests Self-sampling Research Product Manufacturing Development • Affimer® reagents • Market led • High volume • Sampling devices
Slide 40: Coris BioConcept
Coris BioConcept Key Facts Coris by Numbers • Based in Gembloux, Belgium and established in • FY22 £4.6M total revenues (mostly non-COVID 1996, Coris BioConcept develops, manufactures and related) markets rapid diagnostic test kits, mainly lateral flow • Gross margin on sales FY21-22 circa 50%. test
Slide 41: Coris BioConcept Lateral Flow Test Product Range
Coris BioConcept Lateral Flow Test Product Range Anti-microbial Resistance Infectious Diseases • OXA • Giardia/crypto • NDM • Rotavirus/adenovirus • KPC • C.diff GDH • VIM • H.pylori Antibody • IMP • H.pylori Antigen • Carbapenemases • Legionella • CTXM • Adenovirus antigen • Combinations of above •
Slide 42: Spotlight on Anti-microbial Resistance (AMR) Testing
Spotlight on Anti-microbial Resistance (AMR) Testing Antimicrobial Resistance (AMR) occurs when pathogens no longer respond to antimicrobial medicines making infections difficult to treat – testing for AMR is critical A Global Challenge Coris AMR Products • 1.27 million deaths attributable to bacter
Slide 43: Coris BioConcept: Growth Opportunities
Coris BioConcept: Growth Opportunities Opportunities for growth through improved distribution network and broadened product portfolio Distribution Network Product Portfolio Expansion • Improvement in the quality and • Market-led product development management of the distributor and product acquisiti
Slide 44: Differentiation in a Competitive POCT Market
Differentiation in a Competitive POCT Market Affimer® Competitive Advantages Avacta’s proprietary • High specificity and sensitivity. technology with significant • Rapidly generated. technical and commercial • No immune response required. benefits to differentiate • Flexible formatting for different
Slide 45: Summary
Summary Ideal conditions for M&A led growth strategy to consolidate European diagnostics SMEs in a market with strong future growth drivers. Launch Diagnostics: UK/France IVD sales channel into the centralised professional healthcare market for own products, acquired products and third party product
Slide 46: www.avacta.com
www.avacta.com